## CRSP: CRISPR Therapeutics AG - XLV: Healthcare

### Executive Summary

No thesis match: PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($50.38)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. CRISPR Therapeutics stock rating reiterated at Market Outperform by Citizens**
- Source: Investing.com | 20251208T111513 | Somewhat-Bullish | Relevance: 98%
- Citizens has reiterated its Market Outperform rating for CRISPR Therapeutics (NASDAQ:CRSP) with an $86.00 price target, citing its strong stock performance and competitive results in sickle cell disease despite emerging competition. The firm anticipates further positive developments from CRISPR Therapeutics' cell therapy program, particularly an upcoming CTX112 update. While recent Q3 Casgevy sales missed consensus, reduced R&D spending led to a smaller-than-expected loss per share, influencing varied analyst perspectives on the company's future.

**2. Norges Bank Invests $19.77 Million in CRISPR Therapeutics AG $CRSP**
- Source: MarketBeat | 20251209T111100 | Neutral | Relevance: 98%
-  Norges Bank has acquired a new stake of 406,487 shares in CRISPR Therapeutics AG (NASDAQ:CRSP) during the second quarter, valued at approximately $19.77 million, representing about 0.45% of the company. Despite this institutional investment, analyst ratings are mixed with a consensus "Hold" and a target price of $67.42, while company insiders have recently been selling shares. Several other institutional investors also adjusted their positions in CRSP.

**3. State Board of Administration of Florida Retirement System Acquires New Holdings in CRISPR Therapeutics AG $CRSP**
- Source: MarketBeat | 20251207T103023 | Neutral | Relevance: 97%
-  The State Board of Administration of Florida Retirement System has acquired new holdings of 21,361 shares in CRISPR Therapeutics AG (CRSP) during the second quarter, valued at approximately $1.039 million. Despite this new institutional investment and other hedge fund activity, the stock is currently trading down, with a market capitalization of $5.42 billion, and analysts generally hold a "Hold" rating with a consensus target price of $67.42. Insider selling has also been noted, with CEO Samarth Kulkarni reducing his stake.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 4)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-26 | Chardan Capital | $74 | $82 | -10% |
| 2025-11-12 | Citigroup | $77 | $87 | -11% |
| 2025-11-11 | RBC Capital | $50 | $42 | +19% |
| 2025-11-11 | Baird | $44 | $52 | -15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-26 | Chardan Capital | main | Buy |
| 2025-11-12 | Citigroup | main | Buy |
| 2025-11-11 | RBC Capital | main | Sector Perform |
| 2025-11-11 | Baird | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 6 ($3.81M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- ARK Investment Manag: 10.3% (-3.9%)
- Blackrock Inc.: 7.4% (+16.2%)
- Capital Internationa: 5.9% (+1.0%)
- Orbis Allan Gray Ltd: 5.2% (+80.2%)
- State Street Corpora: 4.2% (+22.5%)

### Key Risks

1. Insider selling cluster: $3.8M in recent transactions.
2. High short interest (27.3%, 9.5 days to cover): squeeze risk or crowded bearish bet.
3. Near-term weakness: 6.9% below SMA50 despite long-term uptrend.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Balance sheet: strong liquidity (16.2x), low leverage (D/E 0.17). Revenue growth strong at 1916% YoY. Analyst sentiment negative (4 target cuts vs 1 raises). Insider selling cluster ($3.8M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $5.4B |
| Beta | 1.73 |
| 52W Range | $30.04 - $78.48 |
| Short Interest | 27.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.21 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 5.1% to 3.0% (-2.1% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 84th percentile. MRS_5 (-0.3%) diverging from MRS_10 - short-term weakness emerging. Outperforming sector by 7.5pp, stock-specific strength. MACD histogram positive (1.07), confirming momentum. RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.01% (CS: 84) | Strong |
| RSI_14 | 52.2 | Neutral |
| MACD Histogram | 1.07 | Bullish |
| vs SMA20 | 1.065x | Above |
| vs SMA50 | 0.931x | Below |
| vs SMA200 | 1.127x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $57.04
- **Stop Loss:** $50.38 (11.7% risk)
- **Target:** $63.70 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 45
- **Position Value:** $2,566.80
- **Portfolio %:** 2.57%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-18 (Est: $-1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.29 | $-1.17 | +9.2% |
| 2025Q2 | $-1.40 | $-1.29 | +7.8% |
| 2025Q1 | $-1.28 | $-1.58 | -23.8% |
| 2024Q4 | $-1.19 | $-0.44 | +62.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*